-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Candel Therapeutics, Raises Price Target to $26

Benzinga·03/18/2026 15:03:49
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and raises the price target from $22 to $26.